CN106389425A - 包含PenibruguieramineA用于治疗慢性肾炎的药物组合物 - Google Patents

包含PenibruguieramineA用于治疗慢性肾炎的药物组合物 Download PDF

Info

Publication number
CN106389425A
CN106389425A CN201610925058.6A CN201610925058A CN106389425A CN 106389425 A CN106389425 A CN 106389425A CN 201610925058 A CN201610925058 A CN 201610925058A CN 106389425 A CN106389425 A CN 106389425A
Authority
CN
China
Prior art keywords
penibruguieraminea
ophiopogonin
pharmaceutical composition
treating
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610925058.6A
Other languages
English (en)
Inventor
庄焕迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xuzhou Medical Technology Co Ltd
Original Assignee
Xuzhou Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuzhou Medical Technology Co Ltd filed Critical Xuzhou Medical Technology Co Ltd
Priority to CN201610925058.6A priority Critical patent/CN106389425A/zh
Publication of CN106389425A publication Critical patent/CN106389425A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种包含PenibruguieramineA用于治疗慢性肾炎的药物组合物，有效成分包括PenibruguieramineA，还包括麦冬皂苷B。本发明通过PenibruguieramineA和麦冬皂苷B联合应用，实验结果表明，PenibruguieramineA和麦冬皂苷B在15:1‑17:1对于治疗及其预防慢性肾炎有着很好的效果。

Description

包含PenibruguieramineA用于治疗慢性肾炎的药物组合物
技术领域
本发明涉及一种包含PenibruguieramineA用于治疗慢性肾炎的药物组合物，属于医药技术领域。
背景技术
慢性肾小球肾炎简称慢性肾炎，系指蛋白尿、血尿、高血压、水肿为基本临 床表现，起病方式各有不同，病情迁延，病变缓慢进展，可有不同程度的肾功能 减退，具有肾功能恶化倾向和最终将发展为慢性肾衰竭的一组肾小球病。由于本 组疾病的病理类型及病期不同，主要临床表现可各不相同。疾病表现呈多样化。慢性肾炎可发生于任何年龄，但以青中年为主，男性多见。多数起病缓慢、隐袭。临床表现呈多样性，蛋白尿、血尿、高血压、水肿为其基本临床表现，可 有不同程度肾功能减退，病情时轻时重、迁延，渐进性发展为慢性肾衰竭。实验 室检查多为轻度尿异常，尿蛋白常在1-3g/d，尿沉渣镜检红细胞可增多，可见管型。血压可正常或轻度升高。肾功能正常或轻度受损(肌酐清除率下降或轻度 氮质血症)，这种情况可持续数年，甚至数十年，肾功能逐渐恶化并出现相应的 临床表现(如贫血、血压增高等)，进入尿毒症。如血压控制不好，肾功能恶化较快，预后较差。另外，部分患者因感染、劳 累呈急性发作，或用肾毒性药物后病情急骤恶化，经及时去除诱因和适当治疗后病情可一定程度缓解，但也可能由此而进入不可逆慢性肾衰竭。多数慢性肾炎患 者肾功能呈慢性渐进性损害，病理类型为决定肾功能进展快慢的重要因素(如系膜毛细血管性肾小球肾炎进展较快，膜性肾病进展常较慢)，但也与是合理治疗相关。寻找高效低毒的治疗慢性肾炎药物仍是面临的重要课题。
化合物PenibruguieramineA是Zhen-Fang Zhou , Tibor Kurtán Xiao-HongYang等发表名称为PenibruguieramineA, a Novel Pyrrolizidine Alkaloid from theEndophytic Fungus Penicillium sp. GD6 Associated with Chinese MangroveBruguiera gymnorrhiza发表在Org.Lett.2014,16,1390-1393 ，
是一种全新的化合物结构。目前还未见到关于PenibruguieramineA和麦冬皂苷B在治疗慢性肾炎的报道。
发明内容
针对上述现有技术存在的问题，本发明提供一种包含PenibruguieramineA用于治疗慢性肾炎的药物。
为了实现上述目的，本发明采用的技术方案是：一种包含PenibruguieramineA用于治疗慢性肾炎的药物，有效成分包括PenibruguieramineA，结构式如下：
有效成分包括还包括麦冬皂苷B。
按照重量计算，PenibruguieramineA和麦冬皂苷B比值为1:1-20:1。
本发明提供的一种包含PenibruguieramineA用于治疗慢性肾炎的药物，通过PenibruguieramineA和麦冬皂苷B联合应用，实验结果表明，PenibruguieramineA和麦冬皂苷B在15:1-17:1对于治疗及其预防慢性肾炎具有很好的协同功效。
具体实施方式
上述说明仅是本发明技术方案的概述，为了能够更清楚了解本发明的技术手段，并可依照说明书的内容和本领域的常规技术手段予以实施，以下对本发明的动物试验例做进一步的详细描述。
中文名称:麦冬皂苷B， CAS号: 38971-41-4，南京植佰萃生物科技有限公司等公司均有售。
本发明所涉及化合物PenibruguieramineA的制备方法参见文献：PenibruguieramineA, a Novel Pyrrolizidine Alkaloid from the Endophytic FungusPenicillium sp. GD6 Associated with Chinese Mangrove Bruguiera gymnorrhizaOrg.Lett.2014,16,1390-1393.。
药效试验：
造模：清洁级小鼠, 体重37 ～ 39g , 雄性, 动物室环境温度21℃～ 27℃, 湿度35%～ 45%。220只小鼠随机分为22组，每组10只，分为20组给药组，一组正常组，一组对照组。空白组，对照组给饮用水, 给药组均给予同等容积, 每天灌胃1 次, 连续12 wk 。在灌胃的第1 天同时造模, 正常组不做任何处理。每只小鼠于实验的第1 、7 和10 天腹腔注射葡聚糖凝胶G-150 溶液每只0.5 ml ,浓度2 g•L-1 , 从第15 天开始每周3 次尾静脉注射右旋糖酐(Dextran)每只0.5 ml , 浓度2 g•L-1。共注射12 wk 。
试验方法
尿蛋白含量的测定：12 wk 实验结束时, 将小鼠禁食不禁水, 收集24 h 的尿液,然后采用双缩脲比色法检测尿蛋白含量。
血清BUN 和SCr 含量的测定：12 wk 实验结束时, 将小鼠禁食不禁水, 随后摘眼球取血, 用自动生化分析仪测血清有关指标。
A为PenibruguieramineA, B为麦冬皂苷B。
各组小鼠的的尿蛋白，血清中的BUN 和SCr 含量比较(mg/ L,mmol/L,±s)，
实验结果表明：各组小鼠的尿蛋白，血清中的BUN 和SCr 含量比较，实验后给PenibruguieramineA和为麦冬皂苷B在15:1-17:1两组大鼠的尿蛋白，血清中的BUN 和SCr含量明显低于其它给药组与正常组含量差不多，可见PenibruguieramineA和为麦冬皂苷B在15:1-17:1之间的协同作用对患慢性肾炎小鼠效果最好。

Claims (3)

1.一种包含PenibruguieramineA用于治疗慢性肾炎的药物组合物，其特征在于，有效成分包括PenibruguieramineA，结构式如下：
。
2.根据权利要求1所述的一种包含PenibruguieramineA用于治疗慢性肾炎的药物组合物，其特征在于，有效成分还包括麦冬皂苷B。
3.根据权利要求2所述的一种包含PenibruguieramineA用于治疗慢性肾炎的药物组合物，其特征在于，按照重量计算，PenibruguieramineA和麦冬皂苷B比值为1:1-20:1。
CN201610925058.6A 2016-10-30 2016-10-30 包含PenibruguieramineA用于治疗慢性肾炎的药物组合物 Pending CN106389425A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610925058.6A CN106389425A (zh) 2016-10-30 2016-10-30 包含PenibruguieramineA用于治疗慢性肾炎的药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610925058.6A CN106389425A (zh) 2016-10-30 2016-10-30 包含PenibruguieramineA用于治疗慢性肾炎的药物组合物

Publications (1)

Publication Number Publication Date
CN106389425A true CN106389425A (zh) 2017-02-15

Family

ID=58013345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610925058.6A Pending CN106389425A (zh) 2016-10-30 2016-10-30 包含PenibruguieramineA用于治疗慢性肾炎的药物组合物

Country Status (1)

Country Link
CN (1) CN106389425A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786562A (zh) * 2012-08-16 2012-11-21 西南交通大学 一种吡咯里西啶生物碱及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786562A (zh) * 2012-08-16 2012-11-21 西南交通大学 一种吡咯里西啶生物碱及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHEN-FANG ZHOU等: "Penibruguieramine A, a Novel Pyrrolizidine Alkaloid from the Endophytic Fungus Penicillium sp. GD6 Associated with Chinese Mangrove Bruguiera gymnorrhiza", 《ORGANIC LETTER》 *
陈美娟等: "麦冬皂苷B抑制非小细胞肺癌体内迁移机制的研究", 《第二届国际抑郁共病暨第十二届中国中西医结合基础理论学术研讨会论文集》 *

Similar Documents

Publication Publication Date Title
Kovesdy Updates in hyperkalemia: outcomes and therapeutic strategies
Tayebi Khosroshahi et al. Effect of high amylose resistant starch (HAM‐RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial
Johnson et al. Treatment of renal failure associated with multiple myeloma: plasmapheresis, hemodialysis, and chemotherapy
Mikkelsen et al. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis
Pinho et al. Acute renal failure after Crotalus durissus snakebite: a prospective survey on 100 patients
Rao et al. Golden hours in severe paraquat poisoning-the role of early haemoperfusion therapy
Ghannoum et al. Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP Workgroup
Stegmayr et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis a Swedish multi-center study
Ott et al. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade
Naseef et al. Therapeutic potential of induced iron depletion using iron chelators in Covid-19
Liu et al. Discovery of a novel rice-derived peptide with significant anti-gout potency
Cucchiari et al. Dose-related effects of metformin on acid–base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study
Wu et al. Effect and mechanism of ShiZhiFang on uric acid metabolism in hyperuricemic rats
Umeki et al. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity
Li et al. Organ crosstalk in acute kidney injury: evidence and mechanisms
Biesenbach et al. Nutritional status in type 2 diabetic patients requiring haemodialysis.
Motawi et al. Angiotensin‐converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin‐converting enzyme expression and attenuate renal injury in streptozotocin‐induced diabetic rats
Ismy et al. Superoxide dismutase reduces creatinine and NGAL by restoring oxidative balance during sepsis
Hu et al. Psyllium seed husk regulates the gut microbiota and improves mucosal barrier injury in the colon to attenuate renal injury in 5/6 nephrectomy rats
Gibson et al. Kinetics of salicylate metabolism.
Rajakumar et al. Renal dysfunction in cirrhosis: critical care management
CN106389425A (zh) 包含PenibruguieramineA用于治疗慢性肾炎的药物组合物
Brouhard et al. The combination of lovastatin and enalapril in a model of progressive renal disease
Bueters et al. Impact of early postnatal NSAID treatment on Nephrogenesis in Wistar Rats
CN107812000B (zh) Ps48在制备用于减轻缺血再灌注和顺铂诱导的急性肾损伤相关病症的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170215